PYRIDOXINE
| Chemical Structure |
|
| Drug Class |
VITAMIN B6 / PYRIDOXINE OPHTHALMIC FORMULATION CONCEPT |
| Mechanisms of Action |
THE SUPPLIED MATERIAL DESCRIBES AN OPHTHALMIC PREPARATION
IN WHICH A 0.75 MG RED PYRIDOXINE PELLET IS RECONSTITUTED
IN A SPECIAL SOLVENT. AFTER DISSOLUTION, THE RESULTING
SOLUTION IS DESCRIBED AS CLEAR, NEUTRAL-ACIDIC AND
RANGING IN COLOR FROM ORANGE-RED TO YELLOW. THE TEXT STATES THAT THE PREPARATION IS INTENDED TO PROTECT PYRIDOXINE FROM LIGHT EXPOSURE, WHICH IS DESCRIBED AS CAUSING PHOTODEGRADATION OF THE MOLECULE. THE SOURCE MATERIAL CLAIMS EFFECTS ON QUINONE COMPOUNDS, FAT OXIDATION AND ALDOSE REDUCTASE, AND DESCRIBES A CATARACT-PREVENTION MECHANISM INVOLVING INHIBITION OF QUINONE-ASSOCIATED CONVERSION OF WATER-SOLUBLE LENS PROTEINS INTO INSOLUBLE MATERIAL. THE MATERIAL ALSO DESCRIBES A PROPOSED EFFECT ON CILIARY-MUSCLE FUNCTION AND LENS ACCOMMODATION AFTER ONSET OF THE CONDITION. |
| Monograph |
Chemical Name: PYRIDOXINE Development: OPHTHALMIC RECONSTITUTION CONCEPT USING A 0.75 MG RED PELLET AND SPECIAL SOLVENT. Modern Interest: THE SUPPLIED MATERIAL PRESENTS PYRIDOXINE AS A POSSIBLE OPHTHALMIC AGENT IN CONNECTION WITH PRESBYOPIA, LENS ACCOMMODATION AND CATARACT PROGRESSION. CLAIMED PRESBYOPIA EFFECT: THE SOURCE STATES THAT, IF USED BEFORE ONSET, THE PREPARATION COULD SLOW THE PROGRESSION OF VISION LOSS ASSOCIATED WITH PRESBYOPIA BY APPROXIMATELY 70-80%. AFTER ONSET, IT IS DESCRIBED AS A PROTEIN LINKER DISSOLVER INTENDED TO ALLOW THE CILIARY MUSCLE TO FUNCTION AND MAINTAIN LENS ACCOMMODATION. CATARACT MECHANISM DESCRIBED: QUINONE COMPOUNDS PRODUCED DURING ABNORMAL METABOLISM OF AROMATIC AMINO ACIDS ARE DESCRIBED AS PROMOTING CONVERSION OF WATER-SOLUBLE LENS PROTEINS INTO AN INSOLUBLE FORM, PRODUCING LENS OPACITY. THE SOURCE ATTRIBUTES A CATARACT-PREVENTIVE EFFECT TO INHIBITION OF THESE QUINONE COMPOUNDS. |
| Pharmacokinetic / Experimental Note |
THE SUPPLIED TEXT CITES DATA FROM A STUDY USING
RADIOACTIVELY LABELED HYDROGEN IN RABBITS. FOLLOWING OCULAR INSTILLATION, IT IS REPORTED A TEAR-FLUID CONCENTRATION OF 0.0189 MCG EQ./ML AT 2 HOURS AFTER INSTILLATION, WITH A CONCENTRATION OF 0.003 MCG EQ./ML REPORTED AT 4 HOURS AFTER INSTILLATION. THUS AS AN OPHTHALMIC PREPARATION IT HAS A HALF-LIFE IN THE EYE OF AROUND 8 HOURS. THIS TRANSLATES TO 2 DROPS PER EYE TWO TIMES A DAY. |
| Synthesis batch initiated |
2 (TWO) OPHTHALMIC FORMULATIONS SOURCE MATERIAL | Amount acquired for synthesis: 2 OPHTHALMIC PREPARATIONS | Amount acquired for speculative holding: N/A NOTE: THESE FIGURES REFLECT TOTAL DOCUMENTED ACQUISITIONS. UPDATED MANUALLY |
| OrderBook |
Offer
Bid
|
| Order via | ⧉ Buy Ophtalmic Pyridoxine Preparation |